Clinical Trial

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Study acronym: CHEST RT
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, multi-centre, single arm, phase 2, open label clinical trial of patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) suitable for first-line platinum-based chemotherapy. The aim of the trial is to assess safety, feasibility and describe efficacy of the addition of concurrent thoracic radiotherapy to usual treatment of chemotherapy and immunotherapy (durvalumab) in patients with ES-SCLC.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-21; most recent amendment 2025-08-19.
Status change: Recruiting → Active, Not Recruiting 2025-08-19
Trial Details
NCT Number NCT05796089
Lead Sponsor Trans Tasman Radiation Oncology Group
Collaborators: AstraZeneca
Conditions Extensive-Stage Small-Cell Lung Cancer
Enrollment 35 participants
Start Date 2022-01-01
Primary Completion 2027-09-30 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-08-26